DMEMEDS shared post via Reuters: French biotech Cellectis surges as Pfizer signs cancer drug deal

(Reuters) - U.S. drugmaker Pfizer, which failed last month in a $118 billion bid to buy AstraZeneca, said on Wednesday it had signed a deal with French biotech Cellectis to develop immunotherapy drugs in cancer. [Category: healthNews] http://feeds.reuters.com/~r/reuters/healthNews/~3/0XSrUCJQCT4/story01.htm

Read More